U.S. CAR-T Cell Therapy Market Overview

According to fortune business insights, the U.S. CAR-T cell therapy market size was worth USD 3.00 billion in 2023 and is projected to grow at a CAGR of 18.7% during the forecast period. Chimeric antigen receptor (CAR) T-cell therapy is a novel approach that modifies a patient's T-cells to target and destroy cancer cells. The market growth is driven by the significant rise in the incidence of cancers like leukemia and multiple myeloma, with over 1.2 million Americans developing cancer each year.

Growing awareness and promising results are prompting key players to increase investment in R&D. The market was minimally impacted by the COVID-19 pandemic, as reduced clinical trials were offset by some patients continuing to undergo treatment.

Major Players Profiled in the Market Report:

• Bristol-Myers Squibb Company (U.S.)
• Ferring B.V. (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• Spark Therapeutics, Inc. (U.S.)
• Enzyvant Therapeutics GmbH (U.S.)
• bluebird bio, Inc. (U.S.)
• Gilead Sciences, Inc. (U.S.)
• CARsgen Therapeutics Holdings Limited (China)

Latest Trends

Growing Research and Development Activities for Cell-Based Therapies

The rising prevalence of cancer is fueling demand for more effective treatments, leading to increased investment in R&D for cell-based therapies. Scientific advancements are focused on overcoming existing challenges and introducing new technologies. A 2022 report indicated that there were 750 active CAR-T therapies in development globally, with 375 in clinical phases, highlighting a robust pipeline that is anticipated to drive market growth.

Drivers & Restraints

Increasing Prevalence of Cancer among Population to Spur Market Growth

The growing prevalence of various cancers is a primary driver for the market, stimulating technological advancements and leading to more product approvals. Innovations are also focused on improving efficiency; for example, a clinical trial for a "FasT CAR-T" technology successfully reduced the T-cell manufacturing time to just 24 hours. Regulatory support, such as the FDA's March 2022 approval of Carvykti for adults with multiple myeloma, continues to boost the market.

High Cost Associated with CAR-T Cell Therapy Might Hinder the Market Growth